(secondQuint)CAP-Ketamine for Antidepressant Resistant PTSD.

 In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of three treatment arms (placebo, low dose ketamine, high dose ketamine).

 Participants receive the study drug via intravenous infusion twice per week for 4-weeks.

.

 CAP-Ketamine for Antidepressant Resistant PTSD@highlight

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

